|
1
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Park JA and Cheung NKV: Targets and
antibody formats for immunotherapy of neuroblastoma. J Clin Oncol.
38:1836–1848. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Janoueix-Lerosey I, Schleiermacher G and
Delattre O: Molecular pathogenesis of peripheral neuroblastic
tumors. Oncogene. 29:1566–1579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sylvain NJ, Salman MM, Pushie MJ, Hou H,
Meher V, Herlo R, Peeling L and Kelly ME: The effects of
trifluoperazine on brain edema, aquaporin-4 expression and
metabolic markers during the acute phase of stroke using
photothrombotic mouse model. Biochim Biophys Acta Biomembr.
1863:1835732021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Salman MM, Kitchen P, Woodroofe MN, Bill
RM, Conner AC, Heath PR and Conner MT: Transcriptome analysis of
gene expression provides new insights into the effect of mild
therapeutic hypothermia on primary human cortical astrocytes
cultured under hypoxia. Front Cell Neurosci. 11:3862017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ndunge OB, Kilian N and Salman MM:
Cerebral malaria and neuronal implications of plasmodium falciparum
infection: From mechanisms to advanced models. Adv Sci (Weinh).
9:e22029442022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Salman MM, Kitchen P, Yool AJ and Bill RM:
Recent breakthroughs and future directions in drugging aquaporins.
Trends Pharmacol Sci. 43:30–42. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
López-Soto A, Huergo-Zapico L,
Acebes-Huerta A, Villa-Alvarez M and Gonzalez S: NKG2D signaling in
cancer immunosurveillance. Int J Cancer. 136:1741–1750. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chiossone L, Dumas PY, Vienne M and Vivier
E: Natural killer cells and other innate lymphoid cells in cancer.
Nat Rev Immunol. 18:671–688. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bauer S, Groh V, Wu J, Steinle A, Phillips
JH, Lanier LL and Spies T: Activation of NK cells and T cells by
NKG2D, a receptor for stress-inducible MICA. Science. 285:727–729.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Prajapati K, Perez C, Rojas LBP, Burke B
and Guevara-Patino JA: Functions of NKG2D in CD8+ T cells: An
opportunity for immunotherapy. Cell Mol Immunol. 15:470–479. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mujal AM, Delconte RB and Sun JC: Natural
killer cells: From innate to adaptive features. Annu Rev Immunol.
39:417–447. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zloza A, Kohlhapp FJ, Lyons GE, Schenkel
JM, Moore TV, Lacek AT, O'Sullivan JA, Varanasi V, Williams JW,
Jagoda MC, et al: NKG2D signaling on CD8+ T cells represses T-bet
and rescues CD4-unhelped CD8+ T cell memory recall but not effector
responses. Nat Med. 18:422–428. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Raulet DH: Roles of the NKG2D
immunoreceptor and its ligands. Nat Rev Immunol. 3:781–790. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu H, Wang S, Xin J, Wang J, Yao C and
Zhang Z: Role of NKG2D and its ligands in cancer immunotherapy. Am
J Cancer Res. 9:2064–2078. 2019.PubMed/NCBI
|
|
16
|
Salih HR, Rammensee HG and Steinle A:
Cutting edge: Down-regulation of MICA on human tumors by
proteolytic shedding. J Immunol. 169:4098–4102. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Groh V, Wu J, Yee C and Spies T:
Tumour-derived soluble MIC ligands impair expression of NKG2D and
T-cell activation. Nature. 419:734–738. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pistoia V, Morandi F, Bianchi G, Pezzolo
A, Prigione I and Raffaghello L: Immunosuppressive microenvironment
in neuroblastoma. Front Oncol. 3:1672013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fuertes MB, Domaica CI and Zwirner NW:
Leveraging NKG2D ligands in immuno-oncology. Front Immunol.
12:7131582021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morandi F, Sabatini F, Podestà M and
Airoldi I: Immunotherapeutic strategies for Neuroblastoma: Present,
past and future. Vaccines (Basel). 9:432021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park JR, Digiusto DL, Slovak M, Wright C,
Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg
JR and Jensen MC: Adoptive transfer of chimeric antigen receptor
re-directed cytolytic T lymphocyte clones in patients with
neuroblastoma. Mol Ther. 15:825–833. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pule MA, Savoldo B, Myers GD, Rossig C,
Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, et al:
Virus-specific T cells engineered to coexpress tumor-specific
receptors: Persistence and antitumor activity in individuals with
neuroblastoma. Nat Med. 14:1264–1270. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kailayangiri S, Altvater B, Spurny C,
Jamitzky S, Schelhaas S, Jacobs AH, Wiek C, Roellecke K, Hanenberg
H, Hartmann W, et al: Targeting Ewing sarcoma with activated and
GD2-specific chimeric antigen receptor-engineered human NK cells
induces upregulation of immune-inhibitory HLA-G. Oncoimmunology.
6:e12500502017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pathania AS, Prathipati P, Olwenyi OA,
Chava S, Smith OV, Gupta SC, Chaturvedi NK, Byrareddy SN, Coulter
DW and Challagundla KB: miR-15a and miR-15b modulate natural killer
and CD8+T-cell activation and anti-tumor immune response
by targeting PD-L1 in neuroblastoma. Mol Ther Oncolytics.
25:308–329. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhen Z, Yang K, Ye L, You Z, Chen R, Liu Y
and He Y: HLA-E inhibitor enhances the killing of neuroblastoma
stem cells by co-cultured dendritic cells and cytokine-induced
killer cells loaded with membrane-based microparticles. Am J Cancer
Res. 7:334–345. 2017.PubMed/NCBI
|
|
26
|
Brandetti E, Veneziani I, Melaiu O,
Pezzolo A, Castellano A, Boldrini R, Ferretti E, Fruci D, Moretta
L, Pistoia V, et al: MYCN is an immunosuppressive oncogene
dampening the expression of ligands for NK-cell-activating
receptors in human high-risk neuroblastoma. Oncoimmunology.
6:e13164392017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yan X, Johnson BD and Orentas RJ: Murine
CD8 lymphocyte expansion in vitro by artificial antigen-presenting
cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L
expressed on neuroblastoma expands CD8 tumour-reactive effector
cells in vivo. Immunology. 112:105–116. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zingoni A, Molfetta R, Fionda C, Soriani
A, Paolini R, Cippitelli M, Cerboni C and Santoni A: NKG2D and its
ligands: ‘One for All, All for One’. Front Immunol. 9:4762018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Diefenbach A, Tomasello E, Lucas M,
Jamieson AM, Hsia JK, Vivier E and Raulet DH: Selective
associations with signaling proteins determine stimulatory versus
costimulatory activity of NKG2D. Nat Immunol. 3:1142–1149. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Raffaghello L, Prigione I, Airoldi I,
Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S
and Pistoia V: Downregulation and/or release of NKG2D ligands as
immune evasion strategy of human neuroblastoma. Neoplasia.
6:558–568. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Paschen A, Sucker A, Hill B, Moll I,
Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, et
al: Differential clinical significance of individual NKG2D ligands
in melanoma: Soluble ULBP2 as an indicator of poor prognosis
superior to S100B. Clin Cancer Res. 15:5208–5215. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zingoni A, Vulpis E, Loconte L and Santoni
A: NKG2D ligand shedding in response to stress: Role of ADAM10.
Front Immunol. 11:4472020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hsia HE, Tüshaus J, Brummer T, Zheng Y,
Scilabra SD and Lichtenthaler SF: Functions of ‘A disintegrin and
metalloproteases (ADAMs)’ in the mammalian nervous system. Cell Mol
Life Sci. 76:3055–3081. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng X, Jiang F, Katakowski M, Zhang ZG,
Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant
phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther.
8:1045–1054. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guo W, Huang J, Lei P, Guo L and Li X:
LncRNA SNHG1 promoted HGC-27 cell growth and migration via the
miR-140/ADAM10 axis. Int J Biol Macromol. 122:817–823. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Waldhauer I and Steinle A: Proteolytic
release of soluble UL16-binding protein 2 from tumor cells. Cancer
Res. 66:2520–2526. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Waldhauer I, Goehlsdorf D, Gieseke F,
Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG
and Steinle A: Tumor-associated MICA is shed by ADAM proteases.
Cancer Res. 68:6368–6376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wolpert F, Tritschler I, Steinle A, Weller
M and Eisele G: A disintegrin and metalloproteinases 10 and 17
modulate the immunogenicity of glioblastoma-initiating cells. Neuro
Oncol. 16:382–391. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tosetti F, Venè R, Camodeca C, Nuti E,
Rossello A, D'Arrigo C, Galante D, Ferrari N, Poggi A and Zocchi
MR: Specific ADAM10 inhibitors localize in exosome-like vesicles
released by Hodgkin lymphoma and stromal cells and prevent sheddase
activity carried to bystander cells. Oncoimmunology.
7:e14218892018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Buchanan PC, Boylan KLM, Walcheck B,
Heinze R, Geller MA, Argenta PA and Skubitz APN: Ectodomain
shedding of the cell adhesion molecule Nectin-4 in ovarian cancer
is mediated by ADAM10 and ADAM17. J Biol Chem. 292:6339–6351. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang J, LeBlanc ME, Cano I, Saez-Torres
KL, Saint-Geniez M, Ng YS and D'Amore PA: ADAM10 and ADAM17
proteases mediate proinflammatory cytokine-induced and constitutive
cleavage of endomucin from the endothelial surface. J Biol Chem.
295:6641–6651. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu G, Lu S, Wang X, Page ST, Higano CS,
Plymate SR, Greenberg NM, Sun S, Li Z and Wu JD: Perturbation of NK
cell peripheral homeostasis accelerates prostate carcinoma
metastasis. J Clin Invest. 123:4410–4422. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
de Andrade LF, Tay RE, Pan D, Luoma AM,
Ito Y, Badrinath S, Tsoucas D, Franz B, May KF Jr, Harvey CJ, et
al: Antibody-mediated inhibition of MICA and MICB shedding promotes
NK cell-driven tumor immunity. Science. 359:1537–1542. 2018.
View Article : Google Scholar
|
|
44
|
Zhang J, Liu D, Li G, Staveley-O'Carroll
KF, Graff JN, Li Z and Wu JD: Antibody-mediated neutralization of
soluble MIC significantly enhances CTLA4 blockade therapy. Sci Adv.
3:e16021332017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xiao G, Wang X, Sheng J, Lu S, Yu X and Wu
JD: Soluble NKG2D ligand promotes MDSC expansion and skews
macrophage to the alternatively activated phenotype. J Hematol
Oncol. 8:132015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
André MC, Sigurdardottir D, Kuttruff S,
Pömmerl B, Handgretinger R, Rammensee HG and Steinle A: Impaired
tumor rejection by memory CD8 T cells in mice with NKG2D
dysfunction. Int J Cancer. 131:1601–1610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Perez C, Prajapati K, Burke B, Plaza-Rojas
L, Zeleznik-Le NJ and Guevara-Patino JA: NKG2D signaling certifies
effector CD8 T cells for memory formation. J Immunother Cancer.
7:482019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Quamine AE, Olsen MR, Cho MM and Capitini
CM: Approaches to enhance natural killer cell-based immunotherapy
for pediatric solid tumors. Cancers (Basel). 13:27962021.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu S, Galat V, Galat Y, Lee YKA,
Wainwright D and Wu J: NK cell-based cancer immunotherapy: From
basic biology to clinical development. J Hematol Oncol. 14:72021.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Basher F, Dhar P, Wang X, Wainwright DA,
Zhang B, Sosman J, Ji Z and Wu JD: Antibody targeting tumor-derived
soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival
and function and enhances melanoma response to PDL1 blockade
therapy. J Hematol Oncol. 13:742020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ullrich E, Koch J, Cerwenka A and Steinle
A: New prospects on the NKG2D/NKG2DL system for oncology.
Oncoimmunology. 2:e260972013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kloess S, Huenecke S, Piechulek D, Esser
R, Koch J, Brehm C, Soerensen J, Gardlowski T, Brinkmann A, Bader
P, et al: IL-2-activated haploidentical NK cells restore
NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by
scavenging of plasma MICA. Eur J Immunol. 40:3255–3267. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mastronuzzi A, Colafati GS, Carai A,
D'Egidio M, Fabozzi F, Bufalo FD, Villani MF, Baldo GD, Vennarini
S, Canino C, et al: Central nervous system metastasis in
neuroblastoma: From three decades clinical experience to new
considerations in the immunotherapy era. Cancers (Basel).
14:62492022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Salman MM, Kitchen P, Halsey A, Wang MX,
Törnroth-Horsefield S, Conner AC, Badaut J, Iliff JJ and Bill RM:
Emerging roles for dynamic aquaporin-4 subcellular relocalization
in CNS water homeostasis. Brain. 145:64–75. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kitchen P, Salman MM, Halsey AM,
Clarke-Bland C, MacDonald JA, Ishida H, Vogel HJ, Almutiri S, Logan
A, Kreida S, et al: Targeting aquaporin-4 subcellular localization
to treat central nervous system edema. Cell. 181:784–799.e19. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Salman MM, Al-Obaidi Z, Kitchen P, Loreto
A, Bill RM and Wade-Martins R: Advances in applying computer-aided
drug design for neurodegenerative diseases. Int J Mol Sci.
22:46882021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Aldewachi H, Al-Zidan RN, Conner MT and
Salman MM: High-throughput screening platforms in the discovery of
novel drugs for neurodegenerative diseases. Bioengineering (Basel).
8:302021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wagner K, Unger L, Salman MM, Kitchen P,
Bill RM and Yool AJ: Signaling mechanisms and pharmacological
modulators governing diverse aquaporin functions in human health
and disease. Int J Mol Sci. 23:13882022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Markou A, Unger L, Abir-Awan M, Saadallah
A, Halsey A, Balklava Z, Conner M, Törnroth-Horsefield S, Greenhill
SD, Conner A, et al: Molecular mechanisms governing aquaporin
relocalisation. Biochim Biophys Acta Biomembr. 1864:1838532022.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Papaspyropoulos A, Tsolaki M, Foroglou N
and Pantazaki AA: Modeling and targeting Alzheimer's disease With
Organoids. Front Pharmacol. 11:3962020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Salman MM, Marsh G, Kusters I, Delincé M,
Di Caprio G, Upadhyayula S, de Nola G, Hunt R, Ohashi KG, Gray T,
et al: Design and validation of a human brain endothelial
microvessel-on-a-chip open microfluidic model enabling advanced
optical imaging. Front Bioeng Biotechnol. 8:5737752020. View Article : Google Scholar : PubMed/NCBI
|
